EQUILLIUM, INC.

EQ ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2024 FY2023 FY2022
Revenue $41.1M $36.1M $15.8M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $37.0M $37.5M
SG&A Expense $11.9M $13.6M $17.2M
Operating Income $-8.3M $-14.5M $-62.1M
Operating Margin -20.1% -40.2% -393.9%
Interest Expense $491.0K $1.1M
Pretax Income $-7.7M $-12.8M $-62.4M
Income Tax Expense $361.0K $580.0K $0
Net Income $-8.1M $-13.3M $-62.4M
Net Margin -19.6% -37.0% -396.1%
EPS (Basic) $-0.23 $-0.38 $-1.85
EPS (Diluted) $-0.23 $-0.38 $-1.85
Shares Outstanding (Basic) 35.4M 34.7M 33.7M
Shares Outstanding (Diluted) 35.4M 34.7M 33.7M
Dividends Per Share